Prospeo
Hero Section BackgroundHero Section Background
NanoTherix

NanoTherix Revenue

Biotechnology ResearchFlag of BELeuven, Flemish Region, Belgium1-10 Employees

$

NanoTherix revenue & valuation

Annual revenue$427,775
Revenue per employee$86,000
Estimated valuation?$1,400,000
Total fundingNo funding

Key Contact at NanoTherix

Flag of US

David Bramhill

Chief Technology Officer

Company overview

HeadquartersAmbachtenlaan 1, Heverlee, Flemish Region 3001, BE
Website
NAICS541714
Founded2025
Employees1-10

About NanoTherix

NanoTherix is pioneering NDCentrix®, a fully proprietary Nanobody–Drug Conjugate (NDC) platform that converts single-domain antibodies into next wave precision therapeutics. Our conjugates deliver higher, faster, deeper intratumoral exposure while minimizing healthy-tissue uptake. We are building NDCentrix® as the engine for our own oncology pipeline - where ADCs underperform - and for out-licensing to partners.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

C-Suite

Employees by Department

NanoTherix has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

NanoTherix has never raised funding before.

Frequently asked questions

NanoTherix is located in Leuven, Flemish Region, BE.
NanoTherix generates an estimated annual revenue of $427,775. This revenue figure reflects the company's market position and business performance in its industry.
NanoTherix has an estimated valuation of $1,400,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.
NanoTherix was founded in 2025, making it 1 years old. The company has established itself as a significant player in its industry over this time.
NanoTherix has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

4.8

40,000 users

top 50
high performer
most used
tier 1 accuracy

Build leads list with verified emails & mobiles